Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
MWN-AI** Summary
Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotechnology company focused on developing allosteric small molecule therapies, recently announced its participation in several conferences during the 44th Annual J.P. Morgan Healthcare Conference week. The company will take part in the 9th Annual Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase™, and the LifeSci Advisors Corporate Access Event, providing opportunities for presentations and one-on-one meetings with management.
Gain Therapeutics' lead candidate, GT-02287, is currently in a Phase 1b clinical trial for the treatment of Parkinson’s disease (PD), targeting patients with or without the GBA1 mutation. This drug acts as an allosteric modulator, aiming to restore the function of the lysosomal enzyme glucocerebrosidase (GCase), which is often dysfunctional in mutation carriers. In preclinical studies, GT-02287 has demonstrated promising results, including restoring GCase function, reducing neuroinflammation, and improving motor function in rodent models of PD.
The company announced the primary endpoint of the ongoing Phase 1b study is to evaluate the safety and tolerability of GT-02287 over a three-month period, with participants having the option to continue treatment for an additional nine months in an extension study. Funding for the program has been partially provided by notable foundations, including The Michael J. Fox Foundation and The Silverstein Foundation.
Gain Therapeutics employs its proprietary Magellan™ platform to accelerate drug discovery, particularly for neurodegenerative diseases and other serious conditions. The firm is also exploring applications of GT-02287 for other diseases such as Gaucher’s disease and Alzheimer’s disease, reflecting its commitment to addressing unmet medical needs.
Investors and stakeholders can look forward to insights from the conferences, while Gain Therapeutics continues to advance its innovative therapeutic candidates.
MWN-AI** Analysis
Gain Therapeutics, Inc. (Nasdaq: GANX) has positioned itself as a notable player in the biotechnology sector, particularly with its upcoming participation in several high-profile events during the J.P. Morgan Healthcare Conference Week. This week is pivotal for biotech companies to seek investment and showcase their innovations, and Gain Therapeutics' focus on their lead product, GT-02287, for Parkinson’s disease positions them favorably amidst growing investor interest in neurodegenerative diseases.
GT-02287, targeting a well-defined need within the Parkinson's treatment arena and demonstrating efficacy in preclinical models, reflects potential not just for Parkinson’s but also for related conditions like Gaucher’s disease and Alzheimer’s. The significance of their ongoing Phase 1b clinical trial serves as a critical data point for investors. Moreover, their achievements, such as securing funding from The Michael J. Fox Foundation, enhance credibility and suggest external validation of their research endeavors.
Market conditions are favorable for clinical stage biotechs, particularly those addressing unmet medical needs, as health-focused investors seek opportunities in cutting-edge therapies. Potential stakeholders should consider the upcoming presentations as pivotal moments for gaining insight into GT-02287's progress and efficacy data, which could significantly influence the stock’s trajectory.
However, investors should remain mindful of the inherent risks associated with biotech investments, including the uncertainties of clinical trial results and regulatory approvals. The volatility of such stocks, paired with forward-looking statements in their press releases, necessitates a balanced approach to investment.
In summary, Gain Therapeutics appears poised for potential upside, and those interested in high-risk, high-reward investments may find GT-02287 an intriguing opportunity, particularly following the developments shared during JPM week.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (“JPM week”) including at the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase™, and the LifeSci Advisors Corporate Access Event.
Information on all events is below.
The 9th Annual Sachs Neuroscience Innovation Forum
Date: January 11, 2026
Format: Presentation and one-on-one meetings with management.
Presentation time: 2:40 p.m./ Track C – Rosenberg Room
Location: Marine’s Memorial Club, San Francisco, CA
Demy-Colton/Informa Group Biotech Showcase
Date: January 12-14, 2026
Format: Presentation and one-on-one meetings with management.
Location: Hilton San Francisco Union Square, San Francisco, CA
LifeSci Advisors 15th Annual Corporate Access Event
Date: January 14, 2026
Format: One-on-one meetings with management.
Location: The Beacon Grand, San Francisco, CA
To request an in-person meeting with Gain management on Wednesday during the week of the J.P. Morgan Healthcare Conference, either register at LifeSci Partners Corporate Access Event 2026 or contact our LifeSci Partners representative Alex Grossman (alex@lifesciadvisors.com).
Registered participants of the Biotech Showcase can request an in-person meeting with Gain management by using the Biotech Showcase partnering system.
About GT-02287
Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced ER stress, lysosomal and mitochondrial pathology, aggregated ?-synuclein, neuroinflammation and neuronal death, as well as plasma neurofilament light chain (NfL) levels, a biomarker of neurodegeneration. In rodent models of both GBA1-PD and idiopathic PD, GT-02287 was shown to rescue deficits in motor function and gait and prevent the development of deficits in complex behaviors such as nesting.
GT-02287 is currently being evaluated in a Phase 1b clinical trial for the treatment of Parkinson’s disease with or without a GBA1 mutation. The primary endpoint of the trial, which enrolled participants across seven sites in Australia, is to evaluate the safety and tolerability of GT-02287 after three months of dosing in people with Parkinson’s disease. The recently commenced Phase 1b study extension allows participants to continue to be treated with GT-02287 for up to a total of 12 months.
Gain’s lead program in Parkinson’s disease has been awarded funding support early in its development from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287, including any extension studies; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company’s product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.
Investors:
Gain Therapeutics, Inc.
Apaar Jammu
Manager, Investor Relations and Public Relations
ajammu@gaintherapeutics.com
LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com
Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ**
What specific outcomes does Gain Therapeutics Inc. GANX anticipate from the ongoing Phase clinical trial of GT-02287 for Parkinson's disease, and how will these outcomes influence future clinical development?
How does Gain Therapeutics Inc. GANX plan to leverage the funding support from organizations like The Michael J. Fox Foundation for further development of GT-02287 and other therapies in its pipeline?
What key metrics will Gain Therapeutics Inc. GANX use to evaluate the safety and tolerability of GT-02287 over the extended 12-month treatment period in the Phase 1b trial?
What potential collaborations or partnerships is Gain Therapeutics Inc. GANX exploring to enhance its drug development efforts beyond its current focus on neurodegenerative diseases and lysosomal storage disorders?
**MWN-AI FAQ is based on asking OpenAI questions about Gain Therapeutics Inc. (NASDAQ: GANX).
NASDAQ: GANX
GANX Trading
-9.32% G/L:
$2.5299 Last:
748,982 Volume:
$2.79 Open:
